Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Income from Continuing Operations (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Income from Continuing Operations for 15 consecutive years, with 99230000.0 as the latest value for Q1 2026.

  • For Q1 2026, Income from Continuing Operations fell 9.6% year-over-year to 99230000.0; the TTM value through Mar 2026 reached 423245000.0, down 163.82%, while the annual FY2025 figure was 412781000.0, 161.27% down from the prior year.
  • Income from Continuing Operations hit 99230000.0 in Q1 2026 for Agios Pharmaceuticals, up from 108039000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 947915000.0 in Q3 2024 and bottomed at 112543000.0 in Q2 2025.
  • Average Income from Continuing Operations over 5 years is 33809470.59, with a median of 95847000.0 recorded in 2022.
  • Year-over-year, Income from Continuing Operations surged 1137.97% in 2024 and then tumbled 110.91% in 2025.
  • Agios Pharmaceuticals' Income from Continuing Operations stood at 92684000.0 in 2022, then fell by 3.51% to 95940000.0 in 2023, then fell by 0.61% to 96523000.0 in 2024, then fell by 11.93% to 108039000.0 in 2025, then increased by 8.15% to 99230000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 99230000.0, 108039000.0, and 103433000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.